ЎПКАНИНГ СУРУНКАЛИ ОБСТРУКТИВ КАСАЛЛИГИ ЮРАК ИШЕМИК КАСАЛЛИГИ БИЛАН КОМОРБИДЛИКДА КЕЧИШИНИНГ УЧРАШИ ВА УЛАРНИ ЎЗАРО БИР-БИРИГА ТАЪСИРИ.
Ключевые слова:
ЎСОК,, юрак ишемик касаллиги,, коморбидлик,, юрак-қон томир касалликлари.Аннотация
Ўпканинг сурункали обструктив касаллиги (ЎСОК) дунё бўйича кенг тарқалган бўлиб, 6–26% ҳолларда учрайди. Ўлим сабабларида юрак-қон томир ва ўсмалардан кейин учинчи ўринда туради. Коморбидлик беморларнинг қайта касалхонага ётиши, ногиронлиги ва ўлимини оширади.
Библиографические ссылки
1. Зафираки В.К., Космачева Е.Д. Пациент с ишемической болезнью сердца и хронической обструктивной болезнью легких в эпоху эндоваскулярных вмешательств на коронарных артериях. – М.-Краснодар: Кубанский Государственный Медицинский Университет, 2019. - 286с;
2. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 251-310
3. A.C. Salisbury, K.J. Reid, J.A. Spertus, Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes, Am. J. Cardiol. 99 (2007) 636–641;
4. B. Lamprecht, J.B. Soriano, M. Studnicka, B. Kaiser, L.E. Vanfleteren, L. Gnatiuc, P. Burney, M. Miravitlles, F. García-Rio, K. Akbari, J. Ancochea, A.M. Menezes, R. Perez-Padilla, M. Montes de Oca, C.A. Torres-Duque, A. Caballero, M. Gonz´ alezGarcía, S. Buist, BOLD collaborative Research group, the EPI-SCAN team, the PLATINO team, and the PREPOCOL study group, determinants of underdiagnosis of COPD in national and international surveys, Chest 148 (2015) 971–985;
5. B.Y. Khassawneh, S.M. Samrah, M.I. Jarrah, R.K. Ibdah, A.M. Ibnian, A. W. Almistarehi, A.A. Zghayer, S.I. Abuqudairi, Y.S. Khader, Prevalence of undiagnosed COPD in male patients with coronary artery disease: a cross-sectional study in Jordan, Int. J. Chronic Obstr. Pulm. Dis. 13 (2018) 2759–2766;
6. Barr RG, Ahmed FS, Carr JJ, Hoffman EA, Jiang R, Kawut SM, et al. Subclinical atherosclerosis, airflow obstruction and emphysema: the MESA Lung Study. Eur Respir J. 2012; 39(4):846–54;
7. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res. 2013; 162(4):237–51;
8. Chang CL, Robinson SC, Mills GD et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011; 66 (9): 764–8;
9. Eagan TM, Ueland T, Wagner PD, Hardie JA, Mollnes TE, Damas JK, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J. 2010; 35(3):540–8;
10. Eickhoff P, Valipour A, Kiss D et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178 (12): 1211–8;
11. F.M.E. Franssen, J.B. Soriano, N. Roche, P.H. Bloomfield, G. Brusselle, L.M. Fabbri, F. García-Rio, M.T. Kearney, N. Kwon, B. Lundback, ¨ K.F. Rabe, A. Raillard, H. Muellerova, J.R. Cockcroft, Lung function abnormalities in smokers with ischemic heart disease, Am. J. Respir. Crit. Care Med. 194 (2016) 568–576;
12. Farsang с, Kiss I, Tykarski A, Narkiewicz K. Treatment of Hypertension in Patients With Chronic Obstructive Pulmonary Disease (COPD) Update on Hypertension Management in COPD. Scientific Newsletter. 2016, 17, nr. 62;
13. Ferdaous Yangui, Amany Touil, Saoussen Antit, Lilia Zakhama, Mohamed Ridha Charf. COPD prevalence in smokers with stable ischemic heart disease: A cross-sectional study in Tunisia. Respiratory Medicine 179 (2021), 0954-6111;
14. Gaisl T, Schlatzer C, Schwarz EI, Possner M, Stehli J, Sievi NA, et al. Coronary artery calcification, epicardial fat burden, and cardiovascular events in chronic obstructive pulmonary disease. PLoS One. 2015; 10(5):e0126613;
15. Global Initiative for Chronic Obstructive Lung Disease 2024. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2024 Report; Аверков О.В., Дупляков Д.В., Гиляров М.Ю., Новикова Н.А., Шахнович Р.М., Яковлев А.Н. и др.
16. Henein M, Granasen G, Wiklund U, Schmermund A, Guerci A, Erbel R, et al. High dose and long-term statin therapy accelerate coronary artery calcification. Int J Cardiol. 2015; 184:581–6;
17. Hong Y, Graham MM, Southern D, McMurtry MS. The Association between Chronic Obstructive Pulmonary Disease and Coronary Artery Disease in Patients Undergoing Coronary Angiography. COPD. 2019; 16(1):66–71;
18. Ibanez B, James S, Agewall S et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (2): 119–77;
19. J.B. Soriano, F. Rigo, D. Guerrero, A. Yanez, ˜ J.F. Forteza, G. Frontera, B. Togores, A. Agustí, High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease, Chest 137 (2010) 333–340;
20. Jenny NS, Brown ER, Detrano R, Folsom AR, Saad MF, Shea S, et al. Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2010; 209(1):226–9;
21. K. Onishi, D. Yoshimoto, G.W. Hagan, P.W. Jones, Prevalence of airflow limitation in outpatients with cardiovascular diseases in Japan, Int. J. Chronic Obstr. Pulm. Dis. 9 (2014) 563–568;
22. L. Yin, C. Lensmar, E. Ingelsson, M. Back, ¨ Differential association of chronic obstructive pulmonary disease with myocardial infarction and ischemic stroke in a nation-wide cohort, Int. J. Cardiol. 173 (2014) 601–603;
23. Lin T, Liu JC, Chang LY, Shen CW. Association of C-reactive protein and homocysteine with subclinical coronary plaque subtype and stenosis using low-dose MDCT coronary angiography. Atherosclerosis. 2010; 212(2):501–6;
24. M. Denguezli, H. Daldoul, I. Harrabi, F. Chouikha, H. Ghali, P. Burney, Z. Tabka, Prevalence and characteristics of undiagnosed COPD in adults 40 Years and older - reports from the Tunisian population-based burden of obstructive lung disease study, COPD 1–8 (2020);
25. Maclay JD, MacNee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013; 143(3):798–807;
26. Mota IL, Sousa ACS, Almeida MLD, de Melo EV, Ferreira EJP, Neto JB, et al. Coronary lesions in patients with COPD (Global Initiative for Obstructive Lung Disease stages I-III) and suspected or confirmed coronary arterial disease. Int J Chron Obstruct Pulmon Dis. 2018; 13:1999–2006;
27. P. Almagro, A. Lapuente, J. Pareja, S. Yun, M.E. Garcia, F. Padilla, J.L.I. Heredia, A. De la Sierra, J.B. Soriano, Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study, Int. J. Chronic Obstr. Pulm. Dis. 10 (2015) 1353–1361;
28. Park HY, Lim SY, Hwang JH, Choi JH, Koh WJ, Sung J, et al. Lung function, coronary artery calcification, and metabolic syndrome in 4905 Korean males. Respir Med. 2010; 104(9):1326–35;
29. Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018; 27(149);
30. Reed RM, Eberlein M, Girgis RE, Hashmi S, Iacono A, Jones S, et al. Coronary artery disease is underdiagnosed and under-treated in advanced lung disease. Am J Med. 2012; 125(12):1228 e13– e22;
31. Roffi M, Patrono C, Collet JP et al. Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016 ; 37 (3): 267–315;
32. Ronit A, Kristensen T, Colak Y, Kuhl JT, Kalhauge A, Lange P, et al. Validation of lung density indices by cardiac CT for quantification of lung emphysema. Int J Chron Obstruct Pulmon Dis. 2018; 13:3321– 30;
33. S. Fukuyama, K. Matsumoto, Y. Kaneko, K. Kan-o, N. Noda, Y. Tajiri-Asai, T. Nakano, Y. Ishii, Y. Kiyohara, Y. Nakanishi, H. Inoue, Hisayama pulmonary physiology study group, prevalence of airflow limitation defined by pre- and postbronchodilator spirometry in a community-based health checkup: the hisayama study, Tohoku J. Exp. Med. 238 (2016) 179–184;
34. S.P. Bhatt, M.T. Dransfield, Chronic obstructive pulmonary disease and cardiovascular disease, Transl. Res. 162 (2013) 237–251;
35. Sand JMB, Leeming DJ, Byrjalsen I, Bihlet AR, Lange P, Tal-Singer R et al. High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD – results from the ECLIPSE study. Respiratory Research. 2016;17(1):125;
36. Șerban RC, Hadadi L, Șuș I, Lakatos EK, Demjen Z, Scridon A. Impact of chronic obstructive pulmonary disease on in-hospital morbidity and mortality in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. International Journal of Cardiology. 2017; 243:437–42
37. Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis 2014; 9: 871–88;
38. Thomsen M, Dahl M, Lange P et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186 (10): 982–8;
39. Vaz Fragoso CA, Van Ness PH, Murphy TE, McAvay GJ. Spirometric impairments, cardiovascular outcomes, and noncardiovascular death in older persons. Respir Med. 2018; 137:40–7;
40. Williams MC, Murchison JT, Edwards LD, Agusti A, Bakke P, Calverley PM, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax. 2014; 69(8):718–23;
